Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
2020 ◽
2018 ◽
Vol 36
(26)
◽
pp. 2743-2744
◽
2021 ◽
Vol 77
(18)
◽
pp. 3298